NCT01461720

Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct

An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: National University of Malaysia · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to determine the efficacy of intravenous transplantation of autologous bone marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.

Conditions

• Middle Cerebral Artery Infarction

Interventions

Type	Name	Description
OTHER	Standard medical care	Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
BIOLOGICAL	Autologous bone marrow-derived mesenchymal stem cells	Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-12-01
• Completion: 2016-03-01
• First posted: 2011-10-28
• Last updated: 2015-04-01

Locations

1 site across 1 country: Malaysia